An Open-label, Multicenter Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab (if Given as Part of Local Standard Practice) in Patient With Metastatic Colorectal Adenocarcinoma

NCT00478634 Phase 1 COMPLETED

This study will assess the safety of RAD001 when given together with cetuximab and irinotecan

Details

Lead sponsor	Novartis Pharmaceuticals
Phase	Phase 1
Status	COMPLETED
Enrolment	19
Start date	2007-05
Completion	2009-09

Conditions

• Colorectal Cancer
• Colorectal Carcinoma
• Colorectal Tumors
• Neoplasms, Colorectal

Interventions

• RAD001, Cetuximab, Irinotecan

Primary outcomes

• Dose Limiting Toxicities — at end of cycle 2
  each cycle was 21 days

Countries

United States